<DOC>
	<DOC>NCT00285077</DOC>
	<brief_summary>The primary objective is to assess the long term safety/tolerability of 4 mg/day of SR57667B in comparison to placebo in patients with mild-to-moderate Alzheimer's Disease (AD). A secondary objective is to describe the long term progression of Alzheimer's symptoms in patients treated by 4 mg/day of SR57667B.</brief_summary>
	<brief_title>Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease</brief_title>
	<detailed_description>Multinational, multicenter, randomized, parallel-group, double-blind, phase II study</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients who have participated in Study EFC5286 and completed the study. Patient, identified caregiver and, if applicable, patient surrogate (primary relative, legal guardian, medical proxy) have given their informed written consent and are capable of following study procedures specifically for this LTS5283 extension. Females who are pregnant or breastfeeding. Females of child bearing potential (premenopausal female biologically capable of becoming pregnant) must have a confirmed negative serum bHCG pregnancy test at the screening visit,and must use an acceptable method of birth control.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Alzheimer disease</keyword>
	<keyword>nerve growth factors</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>